OVERVIEW
The market for nuclear medicine is projected to hit USD 5.95 billion by 2025, rising over the forecast period at a CAGR of 4.32 per cent. Growth in the nuclear medicine market can be attributed primarily to factors such as the rising incidence and prevalence of cancer and cardiac ailments and initiatives to minimize Mo-99’s demand-supply gap.
TABLE OF CONTENT
1 Global Nuclear Medicine/Radiopharmaceuticals Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Nuclear Medicine/Radiopharmaceuticals Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Nuclear Medicine/Radiopharmaceuticals Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Nuclear Medicine/Radiopharmaceuticals Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Nuclear Medicine/Radiopharmaceuticals Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Nuclear Medicine/Radiopharmaceuticals Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Nuclear Medicine/Radiopharmaceuticals Market – By Type (Market Size – &
million/billion)
8.1 Diagnostic Nuclear Medicine
8.2 Therapeutic Nuclear Medicine
8.3 Brachytherapy Isotopes
9 Global Nuclear Medicine/Radiopharmaceuticals Market – By Application
9.1 Diagnostic Applications
9.1.1 SPECT Applications
9.1.2 Therapeutic Applications
9.1.3 PET Applications
10 Global Nuclear Medicine/Radiopharmaceuticals Market – By Procedural Volume
Assessment
10.1 Therapeutic Procedures
10.2 Diagnostic Procedures
11 Global Nuclear Medicine/Radiopharmaceuticals Market – By Geography (Market Size – &
million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa
12 Global Nuclear Medicine/Radiopharmaceuticals Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships
13 Global Nuclear Medicine/Radiopharmaceuticals Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Cardinal Health
13.3 Curium
13.4 Bayer AG
13.5 GE Healthcare
13.6 Lantheus Medical Imaging, Inc.
13.7 Nordion, Inc. (A Subsidiary of Sterigenics International)
13.8 Advanced Accelerator Applications (AAA) (A Part of Novartis)
13.9 NTP Radioisotopes Soc, LTD.
13.10 Bracco Imaging S.P.A.
13.11 Eczacibasi-Monrol Nuclear Products
13.12 Company 11 & more
14 Global Nuclear Medicine/Radiopharmaceuticals Market – Appendix
14.1 Sources
14.2 Abbreviations